Guidance and quality standards In consultation
Showing 1 to 4 of 4
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Ritlecitinib for treating severe alopecia areata in people 12 years and over [ID4007] | Draft guidance | Technology appraisal guidance | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [ID6184] | Draft guidance | Technology appraisal guidance | |
| Burosumab for treating X-linked hypophosphataemia in adults [ID3822] | Draft guidance | Technology appraisal guidance | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932] | Draft guidance | Technology appraisal guidance |